283 related articles for article (PubMed ID: 25812839)
1. Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.
Nakasone H; Sahaf B; Miklos DB
Int J Hematol; 2015 May; 101(5):438-51. PubMed ID: 25812839
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Clinical Outcomes and B Cell Immune Reconstitution Following Allo-HCT With Prophylactic, Post-Transplant Rituximab.
Kennedy VE; Sahaf B; Wu F; Ehlinger ZJ; Arai S; Miklos DB
Transplant Cell Ther; 2024 May; 30(5):518.e1-518.e13. PubMed ID: 38458479
[TBL] [Abstract][Full Text] [Related]
3. B cells in chronic graft-versus-host disease.
McManigle W; Youssef A; Sarantopoulos S
Hum Immunol; 2019 Jun; 80(6):393-399. PubMed ID: 30849450
[TBL] [Abstract][Full Text] [Related]
4. B-cell involvement in chronic graft-versus-host disease.
Kapur R; Ebeling S; Hagenbeek A
Haematologica; 2008 Nov; 93(11):1702-11. PubMed ID: 18728020
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.
Kharfan-Dabaja MA; Bazarbachi A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1347-54. PubMed ID: 20083213
[TBL] [Abstract][Full Text] [Related]
6. Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset.
Bohmann EM; Fehn U; Holler B; Weber D; Holler E; Herr W; Hoffmann P; Edinger M; Wolff D
Ann Hematol; 2017 Feb; 96(2):299-310. PubMed ID: 27942862
[TBL] [Abstract][Full Text] [Related]
7. B cells in chronic graft-versus-host disease.
Sarantopoulos S; Blazar BR; Cutler C; Ritz J
Biol Blood Marrow Transplant; 2015 Jan; 21(1):16-23. PubMed ID: 25452031
[TBL] [Abstract][Full Text] [Related]
8. Aberrant B cells, autoimmunity and the benefit of targeting B cells in chronic graft-versus-host disease.
Yehudai-Ofir D; Henig I; Zuckerman T
Autoimmun Rev; 2020 Apr; 19(4):102493. PubMed ID: 32062034
[TBL] [Abstract][Full Text] [Related]
9. CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft-versus-host disease.
Greinix HT; Kuzmina Z; Weigl R; Körmoczi U; Rottal A; Wolff D; Kralj M; Kalhs P; Mitterbauer M; Rabitsch W; Edinger M; Holler E; Pickl WF
Biol Blood Marrow Transplant; 2015 Feb; 21(2):250-8. PubMed ID: 25460358
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
11. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.
Alousi AM; Uberti J; Ratanatharathorn V
Leuk Lymphoma; 2010 Mar; 51(3):376-89. PubMed ID: 20141428
[TBL] [Abstract][Full Text] [Related]
12. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
[TBL] [Abstract][Full Text] [Related]
13. Impact of cGVHD on socioeconomic outcomes in survivors with pediatric hematopoietic stem cell transplant in Japan: a cross-sectional observational study.
Soejima T; Shiohara M; Ishida Y; Inoue M; Hayakawa A; Sato A; Kamibeppu K; Atsuta Y; Yamashita T
Int J Hematol; 2021 Apr; 113(4):566-575. PubMed ID: 33386599
[TBL] [Abstract][Full Text] [Related]
14. XBP-1s Promotes B Cell Pathogenicity in Chronic GVHD by Restraining the Activity of Regulated IRE-1α-Dependent Decay.
Choi HJ; Tang CA; Tian L; Wu Y; Sofi MH; Ticer T; Schutt SD; Hu CA; Yu XZ
Front Immunol; 2021; 12():705484. PubMed ID: 34659198
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib is safe in and stabilizes pulmonary function in patients with allo-HSCT-associated pulmonary CGVHD.
Jain M; Budinger G; Jovanovic B; Dematte J; Duffey S; Mehta J
Bone Marrow Transplant; 2018 Sep; 53(9):1124-1130. PubMed ID: 29523886
[TBL] [Abstract][Full Text] [Related]
16. [Chronic graft-versus-host disease: diagnosis and treatment].
Inamoto Y
Rinsho Ketsueki; 2018; 59(5):549-556. PubMed ID: 29877246
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study.
Malard F; Labopin M; Yakoub-Agha I; Chantepie S; Guillaume T; Blaise D; Tabrizi R; Magro L; Vanhove B; Blancho G; Moreau P; Gaugler B; Chevallier P; Mohty M
Blood; 2017 Nov; 130(20):2186-2195. PubMed ID: 28864814
[TBL] [Abstract][Full Text] [Related]
18. Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD.
van Dorp S; Pietersma F; Wölfl M; Verdonck LF; Petersen EJ; Lokhorst HM; Martens E; Theobald M; van Baarle D; Meijer E; Kuball J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):671-8. PubMed ID: 19450751
[TBL] [Abstract][Full Text] [Related]
19. [Prophylaxis and treatment of chronic graft versus host disease].
Huang K; Li Y; Huang SL; Fang JP; Zhou DH; Chen C
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):174-7. PubMed ID: 15833186
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of Chronic Graft versus Host Disease -Review].
Wang FY; Gao CJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):286-290. PubMed ID: 28245418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
